REG - Physiomics PLC - Completion of Placing, Subscription & Retail Offer

PhysiomicsAnnouncement

29/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230629:nRSc2969Ea&default-theme=true

RNS Number : 2969E  Physiomics PLC  29 June 2023

Unless otherwise defined herein, the capitalised defined terms used in this
announcement have the same meaning as those used in the Company's
announcements released on 27 June 2023 unless otherwise defined herein.

 

29 June 2023

 

Physiomics plc

("PYC" or the "Company")

 

Completion of Fundraise to raise gross proceeds of £380,477

 

Physiomics plc (AIM:PYC) is pleased to announce, further to its announcements
of 27 June 2023, the completion of the Subscription and the WRAP Retail Offer,
as well as the placing of an additional 2,000,000 Ordinary Shares on the same
terms as the Placing (together, the "Fundraise"). The Fundraise, which is
conditional on Admission, raises gross proceeds of, in aggregate, £380,477
through the issue of a total of 38,047,700 new Ordinary Shares (the "Fundraise
Shares").

 

Enlarged Placing

Further to the Company's announcement of 27 June 2023, the Company is pleased
to confirm that it has placed an additional 2,000,000 new Ordinary Shares on
the same terms as the Placing, through Hybridan LLP, taking the total placing
to 34,500,000 new Ordinary Shares raising gross proceeds of, in aggregate,
£345,000.

 

WRAP Retail Offer

The WRAP Retail Offer, which closed at 16:30 BST yesterday, has raised gross
proceeds of £25,477 through the issue of 2,547,700 new Ordinary Shares to
existing retail shareholders in the United Kingdom.

 

Director Subscriptions

Further to the Company's announcement of 27 June 2023, the Company can confirm
that Dr James ('Jim') Millen (Executive Chairman and CEO) and Dr Christophe
Chassagnole (COO) have each subscribed for £5,000 of new Ordinary Shares at
the Placing price pursuant to a direct subscription with the Company and
accordingly will each be issued 500,000 new Ordinary Shares. On Admission, Dr
Millen and Dr Chassagnole will be interested in, in aggregate, 1,884,393 and
1,102,723 Ordinary Shares respectively, representing 1.39% and 0.81% of the
Company's then enlarged issued share capital.

 

Use of Proceeds

In order to further develop its business and accelerate growth, the Company
targeted a raise of around £300,000 with the intention of using the net
proceeds of the Fundraise towards activities including:

·    Further expansion and diversification of its client base;

·    Expansion of its consulting business into the adjacent area of
pharmaceutical biostatistics services; and

·    Exploration of opportunities around its personalised oncology
software offering.

 

Admission and Total Voting Rights

Application has been made for the 38,047,700 Fundraise Shares to be admitted
to trading on AIM, which is expected to take effect and dealings to commence
at 8.00 a.m. on or around 3 July 2023 ("Admission").

 

Following Admission, the Company will have 135,472,478 Ordinary Shares in
issue. Since the Company currently holds no shares in treasury, the total
number of voting rights in the Company will therefore be 135,472,478. These
figures may therefore be used by Shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change in their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO
 
+44 (0)1865 784 980

 

Hybridan LLP (Broker)
 
+44 (0) 203 764 2341

Claire Louise Noyce

 

Strand Hanson Ltd (NOMAD)
 
+44 (0)20 7409 3494

James Dance

James Bellman

 

Winterflood Retail Access Platform
 
WRAP@winterflood.com

Alex Skrine, Head of Electronic Trading
 
+44 (0) 20 3100 0009

Haris Khawaja, Corporate
Finance
 
                                +44 (0) 20 3100
0189

 

 

 

 

The Company's LEI is 213800A71DSZ6ABMTQ91

 

 

PDMR Notification Forms

 

 1.  Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Jim Millen
 2.  Reason for the Notification
 a)  Position/status                                              Executive Chairman and CEO
 b)  Initial notification/amendment                               Initial notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Physiomics plc
 b)  LEI                                                           213800A71DSZ6ABMTQ91
 4.  Details of the transaction(s):section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv)each place
     where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Physiomics plc new Ordinary Shares
     Identification code                                          ISIN:  GB00BDR6W943
 b)  Nature of the Transaction                                    A subscription for new ordinary shares in the Company
 c)  Price(s) and volume(s)                                       Dr Jim Millen

Price(s)  Volume(s)
                                                                  £0.01     500,000

 

 d)  Aggregated information

     -       Aggregated volume                                    500,000

                                                                  £0.01

     -       Price

 e)  Date of the transaction                                      28 June 2023
 f)  Place of the transaction                                     Off market transaction

 

 

d)

Aggregated information

-       Aggregated volume

 

-       Price

 

 

500,000

£0.01

e)

Date of the transaction

28 June 2023

f)

Place of the transaction

Off market transaction

 

 

 1.  Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Christophe Chassagnole
 2.  Reason for the Notification
 a)  Position/status                                              Executive Director, COO
 b)  Initial notification/amendment                               Initial notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Physiomics plc
 b)  LEI                                                           213800A71DSZ6ABMTQ91
 4.  Details of the transaction(s):section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv)each place
     where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Physiomics plc new Ordinary Shares
     Identification code                                          ISIN:  GB00BDR6W943
 b)  Nature of the Transaction                                    A subscription for new ordinary shares in the Company
 c)  Price(s) and volume(s)                                       Dr Christophe Chassagnole

Price(s)  Volume(s)
                                                                  £0.01     500,000
 d)  Aggregated information

     -       Aggregated volume                                    500,000

                                                                  £0.01

     -       Price

 e)  Date of the transaction                                      28 June 2023
 f)  Place of the transaction                                     Off market transaction

d)

Aggregated information

-       Aggregated volume

 

-       Price

 

 

500,000

£0.01

e)

Date of the transaction

28 June 2023

f)

Place of the transaction

Off market transaction

 

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 100 projects, involving over 50 targets and 75 drugs, and
has worked with clients such as Merck KGaA, Astellas, Merck & Co and
Bicycle Therapeutics.

 

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue
of the European Union (Withdrawal) Act 2018, as amended by virtue of the
Market Abuse (Amendment) (EU Exit) Regulations 2019.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFLDRSITFIV